[go: up one dir, main page]

MX2012002082A - Terapia de acetato de glatiramero de baja frecuencia. - Google Patents

Terapia de acetato de glatiramero de baja frecuencia.

Info

Publication number
MX2012002082A
MX2012002082A MX2012002082A MX2012002082A MX2012002082A MX 2012002082 A MX2012002082 A MX 2012002082A MX 2012002082 A MX2012002082 A MX 2012002082A MX 2012002082 A MX2012002082 A MX 2012002082A MX 2012002082 A MX2012002082 A MX 2012002082A
Authority
MX
Mexico
Prior art keywords
glatiramer acetate
multiple sclerosis
low frequency
patient
symptom
Prior art date
Application number
MX2012002082A
Other languages
English (en)
Inventor
Ety Klinger
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43605835&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012002082(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of MX2012002082A publication Critical patent/MX2012002082A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

Se describe un método para aliviar un síntoma de esclerosis múltiple recurrente-con recaída en un paciente humano que padece de esclerosis múltiple recurrente-con recaída o un paciente quien ha experimentado un primer episodio clínico y se determina que está en alto riesgo de desarrollar esclerosis múltiple clínicamente definitiva, que comprende administrar al paciente humano tres inyecciones subcutáneas de una dosis terapéuticamente efectiva de acetato de glatirámero durante un periodo de siete días con al menos un día entre cada inyección subcutánea de manera de aliviar con ello el síntoma del paciente.
MX2012002082A 2009-08-20 2010-08-19 Terapia de acetato de glatiramero de baja frecuencia. MX2012002082A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27468709P 2009-08-20 2009-08-20
US33761210P 2010-02-11 2010-02-11
PCT/US2010/002283 WO2011022063A1 (en) 2009-08-20 2010-08-19 Low frequency glatiramer acetate therapy

Publications (1)

Publication Number Publication Date
MX2012002082A true MX2012002082A (es) 2012-08-23

Family

ID=43605835

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002082A MX2012002082A (es) 2009-08-20 2010-08-19 Terapia de acetato de glatiramero de baja frecuencia.

Country Status (34)

Country Link
US (15) US8399413B2 (es)
EP (5) EP2630962B1 (es)
JP (3) JP6038653B2 (es)
KR (4) KR20140061559A (es)
CN (3) CN105770855A (es)
AR (2) AR077896A1 (es)
AT (1) AT15421U1 (es)
AU (1) AU2010284666B2 (es)
BR (1) BR112012003730A2 (es)
CA (2) CA2760802C (es)
CY (2) CY1114537T1 (es)
CZ (2) CZ30474U1 (es)
DE (1) DE202010018377U1 (es)
DK (5) DK3199172T3 (es)
EA (3) EA032283B1 (es)
ES (4) ES2612001T4 (es)
HK (2) HK1258008A1 (es)
HR (4) HRP20130677T1 (es)
HU (2) HUE031282T2 (es)
IL (3) IL218106A0 (es)
LT (3) LT3199172T (es)
ME (2) ME02662B (es)
MX (1) MX2012002082A (es)
NZ (1) NZ598661A (es)
PL (4) PL2949335T3 (es)
PT (4) PT2405749E (es)
RS (2) RS55607B1 (es)
SG (2) SG10201405806SA (es)
SI (4) SI2630962T1 (es)
SK (1) SK501352015U1 (es)
SM (2) SMT201700057T1 (es)
TW (3) TWI477273B (es)
UA (1) UA103699C2 (es)
WO (1) WO2011022063A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US8077333B2 (en) * 2002-09-09 2011-12-13 Canon Kabushiki Kaisha Printing control apparatus and printing control method
KR20140061559A (ko) * 2009-08-20 2014-05-21 에다 리서치 앤드 디벨럽먼트 컴퍼니 리미티드 글라티라머 아세테이트를 포함하는 약제
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
MX347871B (es) 2010-10-11 2017-05-16 Teva Pharmaceutical Ind Ltd * Biomarcadores de citoquina como marcadores predictivos de respuesta clínica para acetato de glatirámero.
HK1200274A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
HK1213830A1 (zh) 2012-10-10 2016-07-15 Teva Pharmaceutical Industries Ltd. 用於预测醋酸格拉替雷临床反应的生物标志物
PE20151980A1 (es) * 2013-01-04 2016-01-15 Teva Pharma Caracterizacion de un medicamento relacionado con acetato de glatiramer
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN103641897B (zh) * 2013-11-27 2017-01-04 深圳翰宇药业股份有限公司 一种合成醋酸格拉替雷的方法
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
WO2015195605A1 (en) * 2014-06-17 2015-12-23 Teva Pharmaceutical Industries Ltd. Transmucosal delivery of glatiramer acetate by oral patches
CN104844697B (zh) 2014-09-26 2018-10-23 深圳翰宇药业股份有限公司 醋酸格拉替雷的制备方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CN107550853B (zh) * 2016-06-30 2020-06-12 深圳翰宇药业股份有限公司 一种醋酸格拉替雷注射液的制备方法
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
AU2017370937A1 (en) 2016-12-07 2019-05-30 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
MX2019010174A (es) 2017-03-26 2019-10-15 Mapi Pharma Ltd Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple.
WO2019002228A1 (en) 2017-06-26 2019-01-03 Institut Pasteur TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD
WO2019036363A1 (en) 2017-08-14 2019-02-21 Progenity Inc. TREATMENT OF GASTROINTESTINAL TRACT DISEASE WITH GLATIRAMER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
BR112022001138A2 (pt) 2019-07-22 2022-03-15 Actelion Pharmaceuticals Ltd Métodos de tratamento de esclerose múltipla
KR102519053B1 (ko) 2021-02-08 2023-04-06 건국대학교 산학협력단 염산가스의 농도 측정을 위한 수분 전처리 시스템
KR102519054B1 (ko) 2021-03-12 2023-04-06 건국대학교 산학협력단 나피온 드라이어와 수분 전처리장치의 결합시스템
EP4415699A1 (en) * 2021-10-11 2024-08-21 Laboratoires Juvise Pharmaceuticals Methods of treating multiple sclerosis
US12357616B2 (en) 2021-10-11 2025-07-15 Vanda Pharmaceuticals Inc. Methods of treating multiple sclerosis

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
ES2017924B3 (es) 1985-10-11 1991-03-16 Duphar Int Res B V Inyector automatico.
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
IL119989A0 (en) 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
US6454746B1 (en) 1997-06-04 2002-09-24 Eli Lilly And Company Medication delivery apparatus
JP2003521448A (ja) 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
CA2337688C (en) 1998-07-23 2016-04-05 Yeda Research And Development Co., Ltd. Treatment of autoimmune conditions with copolymer 1 and related copolymers
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
ATE516297T1 (de) 1998-09-25 2011-07-15 Yeda Res & Dev Mit copolymer 1 verwandte polypeptide zur verwendung als molekulargewichtsmarker und zur therapeutischen verwendung
AU6281599A (en) 1998-10-02 2000-04-26 Yeda Research And Development Co. Ltd. Alternate day administration of copolymer 1 for treating autoimmune diseases
WO2000027417A1 (en) 1998-11-12 2000-05-18 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd
TR200200472T2 (tr) 1999-08-27 2002-06-21 Genentech, Inc. Anti-Erb B2 antikorları ile tedavi için dozajlar
MXPA02007106A (es) 2000-01-20 2002-12-13 Mcinnis Patricia A El uso del copolimero 1 y peptidos y polipeptidos relacionados y celulas t tratadas con estos para terapia neuroprotectora.
IL150895A0 (en) 2000-02-18 2003-02-12 Teva Pharma Oral, nasal and pulmonary formulations of copolymer-1
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
AU7528001A (en) 2000-06-05 2001-12-17 Teva Pharma The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
ES2256200T3 (es) 2000-06-07 2006-07-16 Yeda Research And Development Co., Ltd. El uso de copolimero 1 y peptidos y polipeptidos relacionados, y de celulas t tratadas con los mismos, para neuroproteccion frente a la toxicidad del glutamato.
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
CA2469393C (en) 2001-12-04 2010-05-25 Teva Pharmaceutical Industries, Ltd. Processes for the measurement of the potency of glatiramer acetate
EP1565486A2 (en) 2002-11-13 2005-08-24 Apotex Pharmachem Inc. Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
EP1572271A1 (de) 2002-11-25 2005-09-14 Tecpharma Licensing AG Autoinjektor mit rückstellbarer auslösesicherung
US7274347B2 (en) 2003-06-27 2007-09-25 Texas Instruments Incorporated Prevention of charge accumulation in micromirror devices through bias inversion
EP1592384B1 (en) 2003-01-21 2012-10-31 Yeda Research And Development Co., Ltd. Cop 1 for treatment of inflammatory bowel diseases
CA2518079A1 (en) * 2003-03-04 2004-10-28 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
SI1638589T1 (sl) 2003-05-14 2014-07-31 Teva Pharmaceutical Industries Ltd. Kombinirana terapija z glatiramer acetatom in mitoksantronom za zdravljenje multiple skleroze
JP2007509981A (ja) 2003-10-31 2007-04-19 テバ ファーマシューティカル インダストリーズ リミティド 薬物デリバリー用ナノ粒子
HUP0303779A2 (en) * 2003-11-20 2006-02-28 Richter Gedeon Vegyeszet Pharmaceutical compositions containing hyaluronan complex for the treatment of sclerosis multiplex
JP2007535498A (ja) 2004-03-03 2007-12-06 テバ ファーマシューティカル インダストリーズ リミティド グラチラマー・アセテートおよびリルゾールでの併用療法
EP1737297B1 (en) * 2004-03-25 2012-12-19 Janssen Pharmaceutica NV Imidazole compounds
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
JP2007536278A (ja) 2004-05-07 2007-12-13 ペプチミューン，インコーポレイテッド ランダム共重合体を用いる疾患の治療方法
US20060194725A1 (en) 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
ES2432369T3 (es) * 2004-06-25 2013-12-03 Id Biomedical Corporation Of Quebec Composiciones y métodos para tratar trastornos neurológicos
EP1796710A4 (en) * 2004-09-02 2010-05-26 Teva Pharma THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS
EP1797109B1 (en) 2004-09-09 2016-02-24 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
SI2177528T1 (sl) 2004-09-09 2012-04-30 Teva Pharma Postopek za pripravo zmesi trifluoroacetil glatiramer acetata z uporabo očiščene bromovodikove kisline
CN101044188B (zh) 2004-10-29 2010-08-04 桑多斯股份公司 制备格拉太咪尔的方法
ZA200705874B (en) 2005-02-02 2009-04-29 Teva Pharma Process for producing polypeptide mixtures using hydrogenolysis
US20100167983A1 (en) 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
SI1848415T1 (sl) 2005-02-17 2013-08-30 Teva Pharmaceutical Industries Ltd. Kombinacijska terapija z glatiramer acetatom in razagilinom za zdravljenje muliple skleroze
WO2006116602A2 (en) 2005-04-25 2006-11-02 Yeda Research And Development Company Markers associated with the therapeutic efficacy of glatiramer acetate
WO2007030573A2 (en) 2005-09-09 2007-03-15 Yeda Research And Development Co. Ltd. Polypeptides useful for molecular weight determinations
WO2007081975A2 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
WO2007146331A1 (en) 2006-06-12 2007-12-21 Teva Pharmaceutical Industries, Ltd. Tannate salt form of polypeptide mixtures, their preparation and use
CN103316403B (zh) 2006-06-30 2017-05-24 艾伯维生物技术有限公司 自动注射装置
EP2046817B1 (en) 2006-07-05 2009-12-16 Momenta Pharmaceuticals, Inc. Improved process for the preparation of copolymer-1
AU2008307565A1 (en) * 2007-10-01 2009-04-09 The Johns Hopkins University Methods of treating neurological autoimmune disorders with cyclophosphamide
WO2009070298A1 (en) 2007-11-28 2009-06-04 Teva Pharmaceutical Industries, Ltd. Method of delaying the onset of clinically definite multiple sclerosis
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
CA2697570C (en) 2009-07-15 2011-11-01 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
KR20140061559A (ko) 2009-08-20 2014-05-21 에다 리서치 앤드 디벨럽먼트 컴퍼니 리미티드 글라티라머 아세테이트를 포함하는 약제
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
MX347871B (es) 2010-10-11 2017-05-16 Teva Pharmaceutical Ind Ltd * Biomarcadores de citoquina como marcadores predictivos de respuesta clínica para acetato de glatirámero.
HK1200274A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
HK1213830A1 (zh) 2012-10-10 2016-07-15 Teva Pharmaceutical Industries Ltd. 用於预测醋酸格拉替雷临床反应的生物标志物
PE20151980A1 (es) 2013-01-04 2016-01-15 Teva Pharma Caracterizacion de un medicamento relacionado con acetato de glatiramer
KR20150138240A (ko) 2013-03-12 2015-12-09 테바 파마슈티컬 인더스트리즈 리미티드 리툭시맙 유도 요법과 글라티라머 아세테이트 요법

Also Published As

Publication number Publication date
US20160250251A1 (en) 2016-09-01
CN107050423A (zh) 2017-08-18
SMT201700057B (it) 2017-03-08
AR077896A1 (es) 2011-09-28
US9155776B2 (en) 2015-10-13
TWI643614B (zh) 2018-12-11
SI2405749T1 (sl) 2013-10-30
SMT201700057T1 (it) 2017-03-08
TW201119645A (en) 2011-06-16
ES2612001T4 (es) 2018-02-07
CY1114537T1 (el) 2016-10-05
TW201521718A (zh) 2015-06-16
US20170196803A1 (en) 2017-07-13
DK201600003U1 (da) 2016-01-22
IL251943A0 (en) 2017-06-29
ME01536B (me) 2014-04-20
RS52885B (sr) 2014-02-28
DK2630962T3 (en) 2018-07-23
EA201691347A3 (ru) 2016-11-30
EP3409286B1 (en) 2020-08-12
CA2760802C (en) 2016-01-12
ES2612001T3 (es) 2017-05-11
RS55607B1 (sr) 2017-06-30
SI2949335T1 (sl) 2017-05-31
EP2630962B1 (en) 2018-06-27
LT2630962T (lt) 2018-10-25
HK1218250A1 (en) 2017-02-10
LT3199172T (lt) 2018-10-25
LT2949335T (lt) 2017-03-27
US20180185274A1 (en) 2018-07-05
US8969302B2 (en) 2015-03-03
PL2405749T3 (pl) 2013-12-31
SI2630962T1 (sl) 2018-10-30
KR20160038057A (ko) 2016-04-06
HRP20170056T2 (hr) 2017-12-15
ES2424692T3 (es) 2013-10-07
US20120071416A1 (en) 2012-03-22
CY1118529T1 (el) 2017-07-12
KR20170123354A (ko) 2017-11-07
US20150250845A1 (en) 2015-09-10
HK1258008A1 (en) 2019-11-01
JP6038653B2 (ja) 2016-12-07
EA201691347A2 (ru) 2016-10-31
EP3199172B1 (en) 2018-07-11
EP3199172A8 (en) 2017-10-11
JP2017132773A (ja) 2017-08-03
UA103699C2 (ru) 2013-11-11
ME02662B (me) 2017-06-20
EP2949335B1 (en) 2017-01-04
TW201733575A (zh) 2017-10-01
EP2405749A4 (en) 2012-08-22
SI3199172T1 (sl) 2018-10-30
EP3199172A1 (en) 2017-08-02
HRP20181254T1 (hr) 2019-01-25
ES2688873T3 (es) 2018-11-07
TWI477273B (zh) 2015-03-21
DK201600003Y3 (da) 2016-02-12
HK1165959A1 (en) 2012-10-19
ES2689711T3 (es) 2018-11-15
HK1225310A1 (zh) 2017-09-08
CZ29723U1 (cs) 2016-08-30
DK3199172T3 (en) 2018-10-08
PL2949335T3 (pl) 2017-07-31
CZ30474U1 (cs) 2017-03-14
HRP20130677T1 (en) 2013-10-11
BR112012003730A2 (pt) 2020-07-21
EA019998B1 (ru) 2014-07-30
HUE031282T2 (hu) 2017-06-28
JP6169644B2 (ja) 2017-07-26
JP2015187125A (ja) 2015-10-29
EP2949335A1 (en) 2015-12-02
KR20140061559A (ko) 2014-05-21
US20110046065A1 (en) 2011-02-24
DK2405749T3 (da) 2013-07-15
CA2760802A1 (en) 2011-02-24
AR099078A2 (es) 2016-06-29
PL3199172T3 (pl) 2019-01-31
EA201270292A1 (ru) 2012-12-28
IL218106A0 (en) 2012-04-30
AU2010284666B2 (en) 2012-12-06
EA019998B9 (ru) 2016-01-29
HRP20181253T1 (hr) 2018-11-02
US20170296464A1 (en) 2017-10-19
CA2876966A1 (en) 2011-02-24
US8399413B2 (en) 2013-03-19
US9402874B2 (en) 2016-08-02
WO2011022063A1 (en) 2011-02-24
US20130165387A1 (en) 2013-06-27
EP2405749A1 (en) 2012-01-18
EP2630962A1 (en) 2013-08-28
EA032283B1 (ru) 2019-05-31
PL2630962T3 (pl) 2018-12-31
PT3199172T (pt) 2018-10-18
AU2010284666A1 (en) 2011-09-22
EP3409286A1 (en) 2018-12-05
US20150202247A1 (en) 2015-07-23
PT2949335T (pt) 2017-02-03
EP2405749B1 (en) 2013-05-08
US20190175494A1 (en) 2019-06-13
US8232250B2 (en) 2012-07-31
CN102625657A (zh) 2012-08-01
US20190054013A1 (en) 2019-02-21
US20170095523A1 (en) 2017-04-06
PT2630962T (pt) 2018-08-01
SG10201405806SA (en) 2014-11-27
SG178495A1 (en) 2012-03-29
KR20120090044A (ko) 2012-08-16
SK501352015U1 (sk) 2017-07-03
EA032287B1 (ru) 2019-05-31
HUE039335T2 (hu) 2018-12-28
US20180311149A1 (en) 2018-11-01
DE202010018377U1 (de) 2016-02-25
PT2405749E (pt) 2013-07-22
US20180064639A1 (en) 2018-03-08
HRP20170056T1 (hr) 2017-03-24
JP2013502415A (ja) 2013-01-24
IL233468A0 (en) 2014-08-31
EA201400394A1 (ru) 2014-10-30
AT15421U1 (de) 2017-08-15
CA2760802F (en) 2011-02-24
CN105770855A (zh) 2016-07-20
US20150164977A1 (en) 2015-06-18
NZ598661A (en) 2013-02-22
DK2949335T3 (en) 2017-07-31

Similar Documents

Publication Publication Date Title
MX2012002082A (es) Terapia de acetato de glatiramero de baja frecuencia.
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
EA201170669A1 (ru) Лечение пирфенидоном пациентов с атипичной функцией печени
CL2024000466A1 (es) Métodos de tratamiento de la insuficiencia cardíaca mediante la administración de omecamtiv mecarbil
WO2011069141A3 (en) Interferon therapies in combination with blockade of stat3 activation
EA201270167A1 (ru) Лекарственная форма глатирамера ацетата с уменьшенным объемом и способы введения
CR9181A (es) Antiangiogenesis terapia de autoinmunidad de enfermedad en pacientes a quienes a fallado la terapia previa
PH12021500006A1 (en) Methods of treatment and prevention of alzheimer's disease
MX2024008350A (es) Metodos para tratar la enfermedad de fabry en pacientes que tienen una mutacion en el gen gla.
NZ608292A (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
MX391565B (es) Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
RU2015103107A (ru) Комбинированная композиция
EA200971073A1 (ru) Применение ранолазина при повышенном уровне натрийуретического пептида мозгового типа
AR103118A1 (es) Tratamientos médicos basados en anamorelina
PE20211199A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
EP4523750A3 (en) Methods of reducing cerebrovascular events in patients with fabry disease
AR121549A2 (es) Terapia de baja frecuencia con acetato de glatiramer
EA201990217A2 (ru) Терапия глатирамером ацетатом с низкой кратностью
ATE495750T1 (de) Sulfatide zur behandlung von autoimmunkrankheiten
EA202192612A1 (ru) Канаглифлозин для лечения больных диабетом пациентов с хроническим заболеванием почек
MD3987C2 (ro) Utilizare a Diosminei pentru tratamentul cirozei hepatice avansate asociate cu insuficienţă cardiacă
MD4232B1 (en) Medicament based on troxerutin and carbazochrome for the treatment of progressive hepatic cirrhosis associated with heart failure
MD3986C2 (ro) Utilizare a Diosminei pentru tratamentul gastropatiilor portale în ciroza hepatică

Legal Events

Date Code Title Description
FG Grant or registration